[HTML][HTML] p38 MAPK inhibition: A promising therapeutic approach for COVID-19

JM Grimes, KV Grimes - Journal of molecular and cellular cardiology, 2020 - Elsevier
COVID-19, caused by the SARS-CoV-2 virus, is a major source of morbidity and mortality
due to its inflammatory effects in the lungs and heart. The p38 MAPK pathway plays a crucial …

[HTML][HTML] Virus-induced p38 MAPK activation facilitates viral infection

Y Cheng, F Sun, L Wang, M Gao, Y Xie, Y Sun, H Liu… - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: Many viral infections are known to activate the p38 mitogen-activated protein
kinase (MAPK) signaling pathway. However, the role of p38 activation in viral infection and …

[HTML][HTML] Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial …

A Faist, S Schloer, A Mecate-Zambrano, J Janowski… - Antiviral research, 2023 - Elsevier
SARS-CoV-2 is the causative agent of the immune response-driven disease COVID-19 for
which new antiviral and anti-inflammatory treatments are urgently needed to reduce …

[HTML][HTML] Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection

FA Robinson, RP Mihealsick… - American Journal …, 2020 - journals.physiology.org
The prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly
reached pandemic proportions, and knowledge about this virus and coronavirus disease …

Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications

N Banu, SS Panikar, LR Leal, AR Leal - Life sciences, 2020 - Elsevier
In light of the outbreak of the 2019 novel coronavirus disease (COVID-19), the international
scientific community has joined forces to develop effective treatment strategies. The …

PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking

C Lugnier, HM Al-Kuraishy, E Rousseau - Biochemical Pharmacology, 2021 - Elsevier
Abstract Angiotensin-converting enzyme 2 (ACE2) is the binding-site and entry-point for
SARS-CoV-2 in human and highly expressed in the lung. Cigarette smoking (CS) is the …

[HTML][HTML] The global phosphorylation landscape of SARS-CoV-2 infection

M Bouhaddou, D Memon, B Meyer, KM White… - Cell, 2020 - cell.com
The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed …

SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management

L Wu, AM O'Kane, H Peng, Y Bi, D Motriuk-Smith… - Biochemical …, 2020 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of …

[HTML][HTML] SARS-CoV-2 infection triggers phosphorylation: potential target for anti-COVID-19 therapeutics

B Chatterjee, SS Thakur - Frontiers in immunology, 2022 - frontiersin.org
The SARS-CoV-2 infection triggers host kinases and is responsible for heavy
phosphorylation in the host and also in the virus. Notably, phosphorylations in virus were …

Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019

YJ Geng, ZY Wei, HY Qian, J Huang, R Lodato… - Cardiovascular …, 2020 - Elsevier
The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major health
crisis, with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) having …